Navigation Links
Our Lady of Lourdes Medical Center & The Heart House Participating in Research Study Using Adult Stem Cells for Chronic Cardiac Condition
Date:6/12/2013

Camden, New Jersey (PRWEB) June 12, 2013

Our Lady of Lourdes Medical Center and The Heart House are participating in a clinical study to determine whether a patient’s own (autologous), adult, stem cells are safe and can relieve chronic chest pain caused by coronary artery disease, as well as increase their ability to walk/exercise.

The RENEW study, sponsored by Baxter Healthcare Corporation and endorsed by the FDA to support a Biologic License Application for investigational CD34+ cell therapy, is a Phase III clinical trial to test the safety and efficacy of CD34+ stem cells. The study is being conducted at only 50 sites in North America and will involve approximately 440 patients.

The Principal Investigator, Vijay Verma, MD, FACC, and Sub-Investigator Andrew Zinn, MD, both interventional cardiologists with Cardiovascular Associates of the Delaware Valley (The Heart House), performed the first procedure at Our Lady of Lourdes Medical Center on April 25, 2013. The patient suffers from severe refractory angina, with two of the three arteries that supply oxygen to the heart completely blocked and is unable to undergo conventional revascularization.

“The patient suffers chest pain every day due to the blockages,” said Dr. Verma. “She has exhausted all other optimal therapies, including angioplasty, bypass surgery and enhanced external counter pulsation (EECP) to relieve the persistent chest pain.”

Patients enrolled in the study are randomly assigned to undergo the procedure or receive the standard of care. Patients in the procedure group are blindly randomized to receive either the stem cells or a placebo.

Forty-eight hours prior to the procedure, Dr. Verma conducted Apheresis procedure to selectively withdraw cells from the patient’s bloodstream. These cells were sent to a special lab where CD34+ cells were extracted and sent back to the hospital for injection into the patient’s heart. Derived from bone marrow, CD34+ cells are comprised of endothelial progenitor cells, which may be able to regenerate heart tissue and develop into new blood vessels. Previous Phase I & Phase II clinical trials have shown that the administration of the CD34+ cells were safe, and a reduction in chest pain and increased ability to exercise was noted in people with myocardial ischemia, or lack of oxygen flow to the heart tissue.

During the nearly four-hour procedure, Dr. Verma and his team created an electrical map of the patient’s heart to locate the damaged area they believed might be causing the chest pain. Using a catheter threaded through the patient’s groin area to the heart, Dr. Verma injected the patient’s CD34+ stem cells into areas of heart muscle with poor blood circulation. Neither Dr. Verma nor the patient knows if the stem cells or a placebo were injected until after the trial is completed and data has been obtained and evaluated.

“We will follow her for the next two years to see whether the injections improve her chest pain and her tolerance to exercise,” said Dr. Verma.

To learn if you are eligible to participate in the study, visit http://www.renewstudy.com.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10825425.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lourdes Doctors Urge Testing During Hepatitis Awareness Month
2. Lourdes Specialty Hospital Offers Unique Treatment Option for Medically Complex Patients with Hyperbaric Oxygen Therapy
3. Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend
4. Physician Groups Call for Fewer Medical Tests
5. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
6. CAM therapy combined with conventional medical care may improve treatment of lower back pain
7. Image share project gives patients and physicians anytime, anywhere access to medical images
8. Researchers determine vitamin D blood level for reducing major medical risks in older adults
9. Biomedical researchers receive Hartwell Foundation awards
10. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
11. Fitness in Middle Age Lowers Medical Costs Later: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... ... 2017 , ... Ecommerce sales have grown every year since the 1990’s, with ... The consequences of rapid innovation and growth are often neglected in the name of ... business and individual’s job to give something back to the planet that provides the ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article in ... teeth, which reveal a great deal about prehistoric ice-age dental practitioners and their primitive ... been used to remove decayed dental matter, and that teeth were then filled with ...
(Date:4/21/2017)... CITY, Utah (PRWEB) , ... April 21, 2017 ... ... of wilderness therapy treatment for adolescents and young adults, has kicked off its ... 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for Mental ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of The Beryl ... 2017 Ruth Ravich Patient Advocacy Award in recognition of her extraordinary contributions ... with the award at The Beryl Institute’s annual Patient Experience Conference on ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness is ... overcome their mental health struggles. The Alive team uses advanced behavioral sciences treatment ... in dealing with a mental health struggle is based on 10 modalities of ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., ... case series to be presented at the 2017 National ... begins today and continues through April 22. Physicians will ... , used to assess risk for acute kidney injury ... heart failure (ADHF). Elevated levels of ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc. and ... started in 2016, in which Socionext extracts and ... The companies achieved initial results in reading ultrasound ... Artificial Brain SOINN. The results will be introduced ... April 19-21, at booths 4505 & 4507. ...
(Date:4/18/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company founded ... infections, will present preclinical data supporting the use of ... (MDR) Gram-negative infections at the 27th European Congress of ... in Vienna, Austria . ... "Our ongoing preclinical ...
Breaking Medicine Technology: